HANSOH PHARMA (03692): Marketing application for Riconlivtutug (HS-20093) for injection for the treatment of osteosarcoma accepted by the National Medical Products Administration

HANSOH PHARMA (03692) announced that on September 24, 2026, the marketing application for the Group's innovative drug HS-20093 for injection (Riconlivtutug for injection) was accepted by China's National Medical Products Administration (NMPA) for the treatment of osteosarcoma patients aged 12 years who have failed at least two prior lines of therapy. HS-20093 for injection is a B7-H3-targeted antibody-drug conjugate (ADC) independently developed by the Group.